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Summary
Purpose : To develop an Italian adaptation of the shortened version of the Quality-of-
Life in Epilepsy Inventory (QOLIE-31).
Methods : The study population comprised 503 consecutive ambulatory patients with
epilepsy from 44 centers. Internal validity was tested by factor analysis, to detect
similarities to and differences from the original version, and by multitrait/multi-item
analysis, to assess item convergent and discriminant validity. External validity testing
included correlation to the SF-36 Inventory, to check the properties of the epilepsy-
specific dimensions. Validity testing was completed by analysis of variance (ANOVA) of
QOLIE-31 dimension scores against demographic and clinical variables, including age,
sex, seizure frequency and number of drugs.
Results : The domains showing the highest internal consistency and the best dis-
criminant validity were Medication effect, and Seizure worry. Social functioning had
the lower discriminant validity. With reference to the SF-36 scores, the study patients
were slightly but constantly below the population values, mostly for General health
and Role physical domains. All QOLIE-31 dimensions were sensitive to almost any
demographic and clinical variable, except forMedication effects (sensitive to number
of drugs) and Energy—fatigue (sensitive to age).
Conclusions : Except for Social functioning, the psychometric properties of the
Italian adaptation of the QOLIE-31 Inventory are fairly good and similar to the
American version and the Spanish translation. Social functioning scale suffers short-
comings because of life constraints caused by epilepsy (with missing values for regular
job and driving license).
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In recent years, health care assessment in epilepsy
has expanded to include the viewpoints of the
patients and their caretakers and to introduce the
concept of health-related quality-of-life (HRQOL) as
a measure of outcome in research and in clinical
practice.1 Several approaches have been adopted in
questionnaires to assess HRQOL in epilepsy.
A first example is the model-driven approach
suggested by researchers from Liverpool University.
Their model includes epilepsy concerns, each ana-
lysed through batteries of validated tests designed
for conditions other than epilepsy.2,3 A second
approach involves newer epilepsy-specific instru-
ments. This is the strategy used, for instance, for
the Social Effect Scale,4,5 the Washington Psycho-
social Seizure Inventory (WSPI),6,7 and the Side
Effects and Life Satisfaction (SEALS).8 Using this
same approach the Liverpool researchers later
developed specific scales within the same original
model, such as the Impact of Epilepsy Scale, the
Mastery Scale and others.9,10
A third approach uses a generic core, such as the
Short Form 36 (SF-36),11,12 supplemented by items
specific toepilepsy.This led toa revised versionof the
Katz Adjustment Scale,13 followed by the ESI-55 for
surgical patients,14 and the Quality-of-Life in Epi-
lepsy Inventory (QOLIE-89)15 with its shortened ver-
sion QOLIE-31.16 The QOLIE-31 was designed to serve
as a brief form to assess epilepsy-specific and some
general HRQOL issues. Cross-cultural translation of
the QOLIE-31 has been completed16 and there is now
a Spanish and a German version.17,18 We set out to
develop an Italian version of the QOLIE-31 Inventory.
Methods
The QOLIE-31 includes 31 items clustered in seven
multi-item scales centered on the following
domains: Overall quality of life, Emotional well-
being, Energy—fatigue, Cognitive functioning,Med-
ication effects, Seizure worry, and Social function-
ing. A scoring system is available for each item (from
0 to 3 or from 0 to 6) and calculated for each scale
(from 0, the worst HRQOL, to 100, the best). Scores
are obtained by dividing the sum of the valid item
scores by the number of items with valid responses
in each scale. An overall score is also produced by
summing the scores of each scale weighted by coef-
ficients obtained by regressing the summary score of
the QOLIE-89 on the seven QOLIE-31 sub-scales
taken as predictors.19
The QOLIE-31 has now been translated and cul-
turally adapted in nine languages (including Italian)by the MAPI Research Institute (Lyon, France).20 One
of us (M.N.) followed the Italian translation and
adaptation of the inventory. The method of adapta-
tion aimed at obtaining the best conceptual equiva-
lence, following the traditional steps of double
translation, back-translation and field testing on
10 patients.
Study plan
The psychometric validation of the QOLIE-31
involved 503 consecutive ambulatory adults with
epilepsy from 44 referral centers. A patient was
considered eligible if she/he was able to understand
and complete the questionnaire. The study plan
included descriptive statistics of the QOLIE-31
scales and reliability assessment (Cronbach’s
alpha). A general distinction can be made between
internal and external validity procedures. Internal
validity, based on scaling properties and consistency
of the sub-scales, was tested through: (a) explora-
tory factor analysis to detect similarities to and
differences from the original experimental version
of the QOLIE-31 Inventory; (b) multitrait/multi-item
analysis (MAP-R)21 to assess item convergent (how
the items belong to the prescribed scale) and dis-
criminant validity (probability of the item belonging
to scales other than those prescribed). External
validity testing included: a) correlation to the SF-
36 Inventory, to check the properties of the epi-
lepsy-specific dimensions, such as Seizure worry and
Medication effect. Correlations with the SF-36
dimensions were assumed as divergent for r < 0.5,
convergent for r = 0.5—0.7, overlapping for r > 0.7;
(b) analysis of variance (ANOVA) of each of the
QOLIE-31 sub-scales against demographic and clin-
ical variables: sex, age, type of seizures, frequency
of seizures, disease duration from diagnosis and
number of antiepileptic drugs (AEDs). Frequency
was adjusted for severity of seizures by ranking
patients in three levels of frequency (low, medium,
high), as suggested by Cramer et al.16 Thus, for
example, 5—12 generalized tonic—clonic seizures
per year correspond to 101—200 simple partial,
absence or myoclonic seizures and are classified
as ‘‘high’’ frequency: 2—4 tonic—clonic seizures
correspond to 21—100 simple partial/absence myo-
clonic seizures and are classified as ‘‘medium’’ fre-
quency; 1 tonic—clonic seizure corresponds to 1—20
simple-partial, absence/myoclonic seizures and is
classified as ‘‘low’’ frequency.
Patients were ranked as having epilepsy diag-
nosed in the last 5 years against all the others having
epilepsy diagnosed earlier. When the span between
diagnosis and test was reduced from 5 to 2 years, the
results were no different.
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the following hypotheses: (1) Seizure worry was
expected to be significantly related to the type/
frequency of seizures and to be worse in patients
with newly-diagnosed epilepsy; (2) Cognitive func-
tioning was expected to fall significantly with age,
frequency of seizures and number of AEDs; (3) Med-
ications effect was expected to rise significantly
with the number of AEDs; (4) Emotional well-being
was expected to be significantly related to sex; (5)
Social functioning was expected to be sensitive to
seizure frequency and number of AEDs; (6) QOLIE-31
total score was expected to be sensitive to the most
important clinical variables, such as seizure fre-
quency and AEDs.Results
Sample characteristics
The sample comprised 258 women (53%) and 226
men (47%) aged 14—80 years (mean 37 years); 312
(62%) had basic education (8 years), 189 (38%) were
formally employed, and 46 (9%) had some disability,
mostly caused by epilepsy. Partial seizures (simple
and/or complex) were present in 160 cases (32%),
followed by generalized tonic—clonic seizures (95,
19%), secondarily generalized seizures (85, 17%),
absence seizures (15, 3%), and other seizure types
(15, 3%). As many as 110 patients (22%) presented
two or more seizure types; 15 (3%) had unclassified
seizures. A total of 245 patients (49%) received
monotherapy, 176 (35%) were treated with two
AEDs, and 79 (16%) with three or more. Seizure-free
patients were 55 (11%). Three quarters (375 cases,
75%) had 1—10 seizures in the preceding month, 45
(9%) 11—30, and 25 (5%) more than 30.Table 1 QOLIE-31 scores (summary statistics).
QOLIE-31 sub-scale No. of
items
Mean S.D. Floo
Seizure worry 5 53.882 26.584 2.2
Overall quality of life 2 62.913 19.454 0.6
Emotional well-being 5 63.860 19.488 0.4
Energy—fatigue 4 57.166 20.320 0.4
Cognitive functioning 6 65.733 24.189 0.2
Medication effects 3 59.837 28.537 4
Social functioning 5 70.561 24.560 0.6
Overall QOLIE-31 30 63.956 18.274 0.2
S.D.: standard deviation.
a Based on 238 out of 503 cases.Descriptive statistics and reliability
For each item, missing values ranged from 1 to 13
(mean 6, corresponding to an average of 1.2%),
except for items 20 (driving) and 27 (working),
included in the Social functioning scale, for which
there were 211 and 168 missing values (41.9 and
33.4% of responses, respectively). As seen above,
the procedure suggested in the Scoring Manual19 was
followed. The problem of missing values was over-
come by dividing the total sum of valid item scores
(transformed on a 0—100 scale) for each patient by
the number of items with valid responses in the
scale. The replacement method suggested for the
SF-36 (missing values = mean of the items with valid
responses in the scale)22 was also used to deal with
the Social functioning scale.
Descriptive statistics of the QOLIE-31 scores are
presented in Table 1. Mean scores ranged from 54 to
71 with large standard deviations. Internal consis-
tency and reliability for almost all domains was
acceptable, Cronbach’s alpha ranging from 0.884
to 0.741. Distribution was skewed for all the scales,
with a tendency for the responses to concentrate
towards the highest scores. This tendency was max-
imal for Medication effects and Social functioning,
with a ceiling effect in respectively 12.9 and 18.7%
of the responses.
Internal validity
As in RAND’s reference study,19 seven factors were
identified from the original main component ana-
lysis, by retaining those with eigenvalues greater
than 1 (see Varimax rotated matrix in the Appendix
A). All items belonging to the QOLIE-31 scales highly
loaded one sole factor (factor loadings greater than
0.5), except for Emotional well-being items which
tended to highly load a factor also loaded by some ofr (%) Ceiling (%) Inter-item correlation
(Pearson’s r)
Alpha
Mean Max Min
4.2 0.522 0.677 0.345 0.842
2.4 0.632 0.632 0.632 0.774
1.4 0.515 0.712 0.275 0.839
1.4 0.513 0.787 0.376 0.808
5.8 0.571 0.780 0.398 0.884
12.9 0.611 0.812 0.485 0.826
18.7 0.385 0.725 0.142 0.741a
0.2 0.876
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Figure 1 SF36 scores in the present sample and in the Italian population (median age). BP: Bodily pain; GH: General
health; MH: Mental health; PF: Physical functioning; RE: Role emotional; RP: Role physical; SF: Social functioning; VT:
Vitality.the Energy—fatigue items, and vice-versa. Items on
the Social functioning scale loaded two factors on
their own. The domains showing the highest mean
inter-item correlations were Overall QOL, Medica-
tion effect, and Seizure worry (Table 1). By con-
trast, the five items in the Social functioning scale
showed a low mean inter-item correlation (r =
0.385). These results are confirmed by the MAP-R
test which indicates full discriminant validity
(100%) for Seizure worry, Cognitive functioning
and Medication effects scales, intermediate with
Emotional well-being and Energy—fatigue scales
(93 and 87%), and lower with the Overall QOL and
Social functioning scales (83%).Table 2 Correlations between QOLIE-31 and SF-36 sub-sca
SF-36/QOLIE-31 SW OQL EWB
BP 0.255 0.355 0.348
GH 0.540 0.755 0.617
MH 0.475 0.676 0.865
PF 0.266 0.440 0.369
RE 0.353 0.542 0.524
RP 0.391 0.549 0.485
SF 0.477 0.652 0.622
VT 0.479 0.718 0.731
BP: Bodily pain; GH: General health; MH: Mental health; PF: Physica
functioning; VT: Vitality; SW: Seizure worry; OQL: Overall quality
Cognitive functioning; ME: Medication effects; SOF: Social functionExternal validity
Comparing the SF-36 scores of the study patients
with the Italian population,22 the two samples had
the same Bodily pain score but differed on the
General health and Role physical scales. For all
the other indices, the patients were slightly but
constantly below the corresponding population
values (Fig. 1, Table 2). By correlating SF-36 and
QOLIE dimensions in the study population and con-
sidering correlations greater than 0.7 (overlapping),
the QOLIE-31 Overall QOL showed a close correla-
tion with SF-36General health and vitality; Energy—
fatigue with SF-36 Vitality; and Emotional well-les.
E—F CO ME SOF QOLIE
0.334 0.289 0.152 0.301 0.376
0.688 0.535 0.367 0.643 0.751
0.709 0.542 0.377 0.575 0.757
0.424 0.537 0.143 0.542 0.560
0.547 0.537 0.272 0.527 0.628
0.514 0.477 0.235 0.557 0.608
0.596 0.609 0.384 0.676 0.753
0.903 0.552 0.350 0.602 0.779
l functioning; RE: Role emotional; RP: Role physical; SF: Social
of life; EWB: Emotional well-being; E—F, Energy—fatigue; CO:
ing; QOLIE: Overall QOLIE.
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Table 3 Correlations between QOLIE-31 scales and external variables.
Sex QOLIE SOF ME CO E—F EWB*** OQL SW***
Age QOLIE *** SOF*** ME CO*** E—F*** EWB*** OQL*** SW
Duration of disease QOLIE *** SOF*** ME CO*** E—F EWB*** OQL*** SW***
Seizures types QOLIE SOF ME CO E—F EW OQL SW***
Seizure frequency QOLIE *** SOF*** ME CO*** E—F EWB*** OQL*** SW***
No. of drugs QOLIE *** SOF*** ME *** CO*** E—F EWB OQL*** SW
QOLIE: Overall QOLIE; SOF: Social functioning; ME: Medication effects; CO: Cognitive functioning; E—F: Energy—fatigue; EWB:
Emotional well-being; OQL: Overall quality of life; SW: Seizure worry.
*** p  0.005 (one-way ANOVA).being with SF-36 Mental health (the last three sub-
scales containing identical items). By contrast, cor-
relations with all the SF-36 dimensions were
divergent (r < 0.5) for Medications effect and Sei-
zure worry (the latter only correlated beyond the
threshold with SF-36 General health). Correlations
were also divergent for the QOLIE-31 dimensions
and SF-36 Bodily pain. Convergence with all the SF-
36 dimensions (r = 0.5—0.7) except Bodily pain was
shown by the QOLIE-31 scales Social functioning and
Cognition.
Applying one-way ANOVA to the demographic and
clinical variables (Table 3) and considering only
highly significant interactions (p < 0.005), the main
results were the following: Medications effect was
sensitive to number of drugs, and Energy—fatigue
only to age; seizure frequency and number of drugs
affected all QOLIE-31 dimensions except Medica-
tions effect (the former) and Energy—fatigue
(both); Emotional well-being was sensitive to sex,
age, disease duration and seizure frequency; Cogni-
tionwas sensitive to age, seizure frequency, disease
duration and number of drugs; seizure type seemed
only to affect Seizure worry. This does not follow the
expected order as to clinical severity since themean
score for primary tonic—clonic seizures was 56.253
compared to 54.092 for complex partial seizures and
49.553 for secondarily generalized seizures.Discussion and conclusion
It would appear that the psychometric properties of
the Italian adaptation of the QOLIE-31 Inventory are
good, and similar to those of the American version14
and its Spanish translation.15 The only real problem
is in the dimension Social functioning. Items like
‘‘driving’’ and ‘‘working’’ had a high rate of missing
values, possibly reflecting constraints caused by
epilepsy. We used two strategies for missing values:
the one recommended by the QOLIE-31 authors and
the SF-36 procedure. When there are only a few
missing values, both give similar results, as in most
of the QOLIE-31 scales. Differences can be substan-
tial, however, when there are several missingvalues. This is the case with the Social functioning
scale where, adopting the Scoring Manual solution,
some scaling psychometrics, such as alpha, item-
scale and inter-item correlations are calculated on a
limited number of patients, mostly those with a
regular job and a driving license (208 out of 503
respondents). As a result alpha is 0.741. Using the
SF-36 procedure and replacing missing values with
the mean of the non-missing values of the items in
the scale, alpha is 0.842. Although it still suffers
from these problems, the first solution is more
reasonable, because patients are questioned only
about aspects that are an actual part of their life,
excluding judgments on driving and working if not
applicable. The second solution artificially increases
the consistency and levels of scores.
With both solutions the Social functioning scale
suffers other shortcomings since the ceiling effect is
18.7% with the first and 15.1% with the second
strategy. On the one hand, driving and working
are important aspects of social life; on the other,
the points made above would undermine consis-
tency because these items apply only to a limited
sub-group of patients. This was the point raised by
patients participating in two focus groups in Italy
prior to this study. As a compromise it was suggested
we should add the item ‘‘not applicable’’ in the
‘‘driving’’ and ‘‘working’’ scales in the Italian ver-
sion of the QOLIE-31. However, though it makes it
easier to complete the questionnaire, this does not
solve the problem.
All other scales show good internal consistency,
with a Cronbach’s alpha greater than 0.8, except for
Overall QOL. This can probably be explained by the
small number of items (two) in the scale. With
reference to Social functioning, four of the five
items spread over three factors in the Varimax
rotated matrix (see Appendix A) probably because
of the problems caused by driving and working,
while items belonging to the other scales agree with
the findings with the same instrument in the USA.
Correlationswith the SF-36 show that the epilepsy-
specific scales Medications effect and Seizure worry
areweakly related to general aspects of HRQOL. As to
the original sources of the QOLIE-31 items, the scales
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Energy—fatigue) show an almost normal distribution
while the remaining scales are skewed, with striking
ceiling effects. This is particularly true forMedication
effects (ceiling effect 13%) and Social functioning
(19%) and, to a lesser extent, for Cognitive function-
ing (6%) and Seizure worry (4%).
Most of the construct validity hypotheses were
met, as shown in Table 3. As expected, Seizure
worry was significantly related to Seizure fre-
quency. Cognitive functioning was significantly
related to the deterioration due to age, frequency
of seizures and AEDs, while Medication effects
increased with the number of drugs. Emotional
well-being was related to sex and decreased sig-
nificantly with age. Finally, the overall QOLIE-31
score was sensitive to seizure frequency and number
of drugs, and was lower in older patients.
The construct validity hypotheses that were not
met included Type of seizures, which were signifi-
cantly related to Seizure worry, but the highest
scores did not correspond to the clinical severity ofAppendix A. Varimax rotated matrix
Factor 1 Factor 2 Factor 3 F
SW1 0.15162 0.22128 0.32136 0
SW2 0.19662 0.19565 0.12637 0
SW3 0.18370 0.16513 0.11391 0
SW4 0.17800 0.18280 0.10515 0
SW5 0.19485 0.05624 0.02746 0
OQL1 0.61171 0.22768 0.17733 0
OQL2 0.63431 0.29574 0.18308 0
EWB1 0.13345 0.10692 0.76392 0
EWB2 0.34457 0.24656 0.69648 0
EWB3 0.71269 0.11899 0.29843 0
EWB4 0.40728 0.17432 0.66377 0
EWB5 0.82057 0.08264 0.17017 0
E—F1 0.81508 0.11760 0.20795 0
E—F2 0.81962 0.11420 0.21779 0
E—F3 0.14174 0.24664 0.73211 0
E—F4 0.27858 0.20183 0.65502 0
CO1 0.16523 0.57350 0.31198 0
CO2 0.20926 0.79492 0.11219 0
CO3 0.13737 0.82771 0.23725 0
CO4 0.09076 0.76435 0.19503 0
CO5 0.13398 0.76474 0.18459 0
CO6 0.14043 0.55482 0.09394 0
ME1 0.17109 0.07215 0.15903 0
ME2 0.10413 0.08116 0.03868 0
ME3 0.11680 0.13814 0.06894 0
SOF1 0.31899 0.35072 0.32311 0
SOF2 0.13684 0.32270 0.19511 0
SOF3 0.18330 0.03273 0.03313 0
SOF4 0.12288 0.09246 0.14685 0
SOF5 0.26050 0.25762 0.09051 0
SW: Seizure worry; OQL: Overall quality of life; EWB: Emotional w
Medication effects; SOF: Social functioning.seizures. In addition, Duration of disease did not
seem to follow what is reported about newly diag-
nosed seizures.23 Patients with epilepsy diagnosed
during the last 5 years did not have different scores
from those with longer-dating disease on any of the
QOLIE-31 dimensions. These apparently contrasting
findings can be interpreted by assuming that HRQOL
in patients with epilepsy is not significantly affected
by seizure severity anddiseaseduration. Cultural and
social factors may play a role, making comparisons
across countries difficult for these specific aspects.
The correlation between several demographic
and clinical variables and Social functioning, Cog-
nitive functioning and Overall QOL show that the
QOLIE-31 includes aspects that are suitable for a
comprehensive assessment and evaluation of
patients with epilepsy.
In conclusion, even with some limitations, the
Italian version of the QOLIE-31 Inventory shows
fairly good reliability, internal and external validity,
supporting its use as a specific measure of the
HRQOL in epilepsy in Italy.actor 4 Factor 5 Factor 6 Factor 7
.62122 0.09081 0.35584 0.03959
.78034 0.09517 0.23017 0.00653
.69049 0.08812 0.10391 0.07003
.78087 0.14026 0.04798 0.03020
.64532 0.26040 0.13413 0.37805
.10133 0.08074 0.31454 0.13335
.20948 0.15296 0.26204 0.10883
.16716 0.06649 0.08420 0.16517
.07402 0.06840 0.16418 0.11479
.21108 0.15423 0.09181 0.14995
.09322 0.06199 0.18466 0.07586
.15409 0.05119 0.10153 0.04054
.18843 0.16248 0.11689 0.04466
.16883 0.12376 0.06650 0.04382
.05400 0.11138 0.22741 0.00160
.15320 0.05292 0.09445 0.05631
.13206 0.10509 0.40358 0.02223
.15509 0.06641 0.00416 0.10812
.08939 0.07053 0.06887 0.04228
.18722 0.07693 0.22644 0.00221
.25303 0.11427 0.21171 0.05356
.14852 0.35780 0.15048 0.43828
.24309 0.69383 0.00498 0.19979
.10792 0.87666 0.10082 0.19134
.09479 0.85307 0.06084 0.20952
.10095 0.16701 0.60088 0.03364
.29384 0.16716 0.62371 0.00290
.14255 0.04151 0.59327 (0.42886)
.07619 0.17846 0.16082 0.80258
.15783 0.50284 0.16987 (0.43662)
ell-being; E—F: Energy—fatigue; CO: Cognitive functioning; ME:
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